Presentation
Poolbeg Pharma Presentation
See all presentationsHeadquartered in London and publicly traded on the London Stock Exchange & the OTC Markets in the US
AIM: POLB | OTCQB: POLBF
Poolbeg Pharma plc is committed to the development and commercialisation of innovative medicines that address critical unmet medical needs. We are focused on strategically commercialising approved and marketed drugs to fund the development of our robust pipeline of innovative products, driving significant value creation.
Reasons to Invest
Industry Leading Team
- Experienced executive team successfully built three public life science companies & achieved multiple exits
- Three key former Amryt Pharma leaders joined Poolbeg with a track record of establishing and scaling sales infrastructures in the US & ROW
Revenue Focused Business Model
- Targeting near term revenue generation from commercial stage rare and orphan products
- Focused on partnering to maximisevalue from in-house programmes
High Value Programmes for Partnering
- POLB 001 – Phase 2 ready ->$10bn market opportunity in cancer immunotherapy-induced CRS. Treatment for severe influenza
- Oral encapsulation technology – targeting obesity with Oral GLP-1R agonist – entering clinic in 2024
- AI-led discovery programmes with CytoReason (Influenza) and OneThree Biotech (RSV)
Strong Financial Position
- Cash balance of £14.1m (30 June 2023)
- Pivoting to revenue generation and cashflows
